Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.53 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.53 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.53 |
| ▸ | PAOX | Q6QHF9 | 3/20 | 0.46 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.44 |
| ▸ | CES2 | O00748 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | FAAH | O00519 | 1/20 | 0.36 |
| ▸ | PLA2G2C | Q5R387 | 1/20 | 0.36 |
| ▸ | ACHE | P22303 | 5/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21106780 | 0.87 | CYP2C19 (0.41) | KDM4EMAPK1HIF1ACES2CYP2C19 | |
| SCHEMBL24029441 | 0.85 | KDM4E (0.52) | KDM4EMAPK1HIF1APAOXADRA1A | |
| SCHEMBL22856128 | 0.84 | MEN1 (0.53) | CES2CYP2C19EPHX2FAAHACHE | |
| SCHEMBL24607183 | 0.84 | CYP2C19 (0.45) | CYP2C19EPHX2 | |
| SCHEMBL22861923 | 0.83 | MEN1 (0.50) | KDM4EMAPK1HIF1APAOXL3MBTL1 | |
| SCHEMBL22790989 | 0.83 | MEN1 (0.50) | KDM4EMAPK1HIF1APAOXL3MBTL1 | |
| SCHEMBL23945213 | 0.83 | MEN1 (0.50) | KDM4EMAPK1HIF1APAOXL3MBTL1 | |
| SCHEMBL20234764 | 0.83 | CYP2C19 (0.39) | KDM4ECES2CYP2C19EPHX2L3MBTL1 | |
| SCHEMBL24673615 | 0.83 | CYP2C19 (0.38) | KDM4ECES2CYP2C19EPHX2ACHE | |
| SCHEMBL23696036 | 0.83 | CYP2C19 (0.38) | KDM4EMAPK1HIF1ACES2CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230219945-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2023-07-13 | — | — | US | disclosed |
| US-20230072658-A1 | SMARCA DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2023-03-09 | — | — | US | disclosed |
| US-11352350-B2 | IRAK degraders and uses thereof | KYMERA THERAPEUTICS, INC. (US) | 2022-06-07 | — | — | US | disclosed |
| US-20210323952-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2021-10-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11352350-B2 | IRAK degraders and uses thereof | IRAK2, IRAK3, IRAK1 | KDM4E 190/4885MAPK1 2017/4885HIF1A 3588/4885 |
| US-20210323952-A1 | IRAK DEGRADERS AND USES THEREOF | IRAK2, IRAK3, IRAK1 | KDM4E 190/4885MAPK1 2017/4885HIF1A 3588/4885 |
| US-20230219945-A1 | IRAK DEGRADERS AND USES THEREOF | IRAK2, IRAK3, IRAK1 | KDM4E 190/4885MAPK1 2017/4885HIF1A 3588/4885 |
| US-20230072658-A1 | SMARCA DEGRADERS AND USES THEREOF | SMARCA1, SMARCB1, SMARCE1 | KDM4E 624/4885MAPK1 2163/4885HIF1A 2282/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.